**Supplemental Digital Content 8.** Proportion and Duration of Second-Line Monotherapy by Medication

|  |  |  |  |
| --- | --- | --- | --- |
| **Medication** | **Total****N=1130** | **Commercial n=750** | **Medicare n=380** |
| Carbamazepine, second-line monotherapy, n (%) | 338 (29.9) | 211 (28.1) | 127 (33.4) |
| Duration (days) | Median (IQR) | 90 (30–269) | 80 (30–210) | 145 (35–371) |
| Mean (SD) | 204 (252) | 174 (230) | 252 (279) |
| Gabapentin, second-line monotherapy, n (%) | 364 (32.2) | 231 (30.8) | 133 (35) |
| Duration (days)  | Median (IQR) | 90 (30–253) | 64 (30–198) | 134 (30–366) |
| Mean (SD) | 199 (255) | 172 (241) | 245 (272) |
| Oxcarbazepine, second-line monotherapy, n (%) | 165 (14.6) | 110 (14.7) | 55 (14.5) |
| Duration (days)  | Median (IQR) | 90 (30–370) | 85 (30–342) | 103 (36–547) |
| Mean (SD) | 248 (305) | 231 (297) | 282 (319) |
| Pregabalin, second-line monotherapy, n (%) | 138 (12.2) | 96 (12.8) | 42 (11.1) |
| Duration (days) | Median (IQR) | 133 (30–344) | 121 (30–339) | 181 (79–388) |
| Mean (SD) | 256 (295) | 239 (290) | 294 (307) |
| Topiramate, second-line monotherapy, n (%) | 47 (4.2) | 43 (5.7) | 4 (1.1) |
| Duration (days) | Median (IQR) | 61 (30–128) | 65 (30–130) | 30 (30–38) |
| Mean (SD) | 121 (186) | 129 (192) | 34 (8) |
| Duloxetine, second-line monotherapy, n (%) | 41 (3.6) | 32 (4.3) | 9 (2.4) |
| Duration (days) | Median (IQR) | 138 (47–403) | 137 (39–369) | 322 (104–540) |
| Mean (SD) | 300 (339) | 286 (343) | 348 (340) |
| Baclofen, second-line monotherapy, n (%) | 37 (3.3) | 27 (3.6) | 10 (2.6) |
| Duration (days) | Median (IQR) | 41 (30–144) | 42 (25–153) | 32 (30–90) |
| Mean (SD) | 142 (238) | 172 (272) | 59 (50) |

IQR, interquartile range.